Digital health firm Eko Devices has released the second generation of its CORE digital stethoscope technology to enable medical professionals to screen for heart ailments.
The new version of CORE offerings will be available either as a fully assembled digital stethoscope (CORE Digital Stethoscope) or as an attachment for most existing stethoscopes (CORE Digital Attachment).
CORE Digital Attachment and CORE Digital Stethoscope will be available on Eko’s website to the healthcare providers for $199 and $249, respectively.
The redesigned Eko core features active noise cancellation, sleeker design and upgraded software.
Eko co-founder and CEO Connor Landgraf said: “When heart and lung sounds are amplified in the screening of heart valve and pulmonary diseases, everything changes.
“Our mission at Eko continues to be to enable all healthcare professionals to provide the highest level of cardiac care through non-invasive, reliable products. The redesigned CORE puts the ears of a trained cardiologist in the hands of any doctor or nurse.”
The company claims that the offerings will overcome the barriers associated with the analogue stethoscopes.
Eko clinical research vice president Steve Pham said: “The better we can hear and the better we can screen, the better we can care for our patients. The CORE, coupled with Eko’s software, helps convert the device already worn around the neck of 30 million clinicians around the world into a powerful cardiopulmonary screening tool.”
CORE Digital Attachment and CORE Digital Stethoscope claim the products come with up to 40x sound amplification, active noise cancellation, as well as wireless Bluetooth connectivity.
By using Eko’s redesigned core, healthcare providers can easily switch between acoustic and digital modes.
It also comes with a lithium-ion battery, with a battery back-up of up to 10 hours.
With a one-click recording button, Eko’s software allows users to save recordings and share them with others.
Waveforms and phonocardiograms can also be viewed through the app.
Eko has also developed screening algorithms to help clinicians analyse heartbeats, which is currently awaiting FDA approval.